Subcutaneous Orencia approved for use in adults either as monotherapy or in combination with nonbiologic DMARDs. FDA approved a subcutaneous formulation of Bristol-Myers Squibb’s fusion protein drug ...
Please provide your email address to receive an email when new articles are posted on . Bristol-Myers Squibb Company announced Orencia intravenous infusion and subcutaneous injection in combination ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results